Cambridge biotech bluebird bio (Nasdaq: BLUE) set a price tag of $1.8 million over five years (315,000 euros per year, or the equivalent of $356,000 annually) for its first commercial drug on Friday, for which it received approval to sell in Europe last week.

Zynteglo treats beta thalassemia, an inherited blood condition that leads to low levels of red blood cells and oxygen in the blood. The overall condition is fairly common, according to the NIH, but children and adults with severe forms of…

Boston Biz Journal https://www.bizjournals.com/boston/news/2019/06/14/bluebird-prices-gene-therapy-in-europe-at-1-8m.html?ana=RSS&s=article_search